Cargando…

Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development

The emergence of COVID19 pandemic caused by SARS-CoV-2 virus has created a global public health and socio-economic crisis. Immunoinformatics-based approaches to investigate the potential antigens is the fastest way to move towards a multiepitope-based vaccine development. This review encompasses the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Apoorva, Madan, Riya, Singh, Swati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444117/
https://www.ncbi.nlm.nih.gov/pubmed/36064873
http://dx.doi.org/10.1007/s00284-022-03003-3
_version_ 1784783145290170368
author Pandey, Apoorva
Madan, Riya
Singh, Swati
author_facet Pandey, Apoorva
Madan, Riya
Singh, Swati
author_sort Pandey, Apoorva
collection PubMed
description The emergence of COVID19 pandemic caused by SARS-CoV-2 virus has created a global public health and socio-economic crisis. Immunoinformatics-based approaches to investigate the potential antigens is the fastest way to move towards a multiepitope-based vaccine development. This review encompasses the underlying mechanisms of pathogenesis, innate and adaptive immune signaling along with evasion pathways of SARS-CoV-2. Furthermore, it compiles the promiscuous peptides from in silico studies which are subjected to prediction of cytokine milieu using web-based servers. Out of the 434 peptides retrieved from all studies, we have identified 33 most promising T cell vaccine candidates. This review presents a list of the most potential epitopes from several proteins of the virus based on their immunogenicity, homology, conservancy and population coverage studies. These epitopes can form a basis of second generation of vaccine development as the first generation vaccines in various stages of trials mostly focus only on Spike protein. We therefore, propose them as most potential candidates which can be taken up immediately for confirmation by experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00284-022-03003-3.
format Online
Article
Text
id pubmed-9444117
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94441172022-09-06 Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development Pandey, Apoorva Madan, Riya Singh, Swati Curr Microbiol Review Article The emergence of COVID19 pandemic caused by SARS-CoV-2 virus has created a global public health and socio-economic crisis. Immunoinformatics-based approaches to investigate the potential antigens is the fastest way to move towards a multiepitope-based vaccine development. This review encompasses the underlying mechanisms of pathogenesis, innate and adaptive immune signaling along with evasion pathways of SARS-CoV-2. Furthermore, it compiles the promiscuous peptides from in silico studies which are subjected to prediction of cytokine milieu using web-based servers. Out of the 434 peptides retrieved from all studies, we have identified 33 most promising T cell vaccine candidates. This review presents a list of the most potential epitopes from several proteins of the virus based on their immunogenicity, homology, conservancy and population coverage studies. These epitopes can form a basis of second generation of vaccine development as the first generation vaccines in various stages of trials mostly focus only on Spike protein. We therefore, propose them as most potential candidates which can be taken up immediately for confirmation by experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00284-022-03003-3. Springer US 2022-09-05 2022 /pmc/articles/PMC9444117/ /pubmed/36064873 http://dx.doi.org/10.1007/s00284-022-03003-3 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Pandey, Apoorva
Madan, Riya
Singh, Swati
Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title_full Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title_fullStr Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title_full_unstemmed Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title_short Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
title_sort immunology to immunotherapeutics of sars-cov-2: identification of immunogenic epitopes for vaccine development
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444117/
https://www.ncbi.nlm.nih.gov/pubmed/36064873
http://dx.doi.org/10.1007/s00284-022-03003-3
work_keys_str_mv AT pandeyapoorva immunologytoimmunotherapeuticsofsarscov2identificationofimmunogenicepitopesforvaccinedevelopment
AT madanriya immunologytoimmunotherapeuticsofsarscov2identificationofimmunogenicepitopesforvaccinedevelopment
AT singhswati immunologytoimmunotherapeuticsofsarscov2identificationofimmunogenicepitopesforvaccinedevelopment